Study Reveals Novo Nordisk’s Ozempic Production Costs Under $5 a Month

Ozempic, a popular drug for diabetes and obesity, is at the center of a new study that reveals shocking insights into the cost of production versus the high prices charged in the US. The study, conducted by researchers at Yale University, King’s College Hospital in London, and Doctors Without Borders, found that Ozempic could be manufactured for as little as 89 cents to $4.73 for a month’s supply, including a profit margin.

This stark contrast to the monthly US list price of $968.52 for Ozempic has reignited the debate on drug pricing and affordability. Novo Nordisk A/S, the maker of Ozempic, declined to provide production costs but stated that they are making significant investments to ensure access to their drugs. However, critics like Senator Bernie Sanders have called for a drastic reduction in the list price to make it more affordable for patients.

The study highlights the immense profit margins on drugs like Ozempic, raising questions about what constitutes a fair price for life-saving medications. Novo’s combined sales of Ozempic and its related drug Wegovy exceeded $18 billion in 2023, indicating the massive financial impact of these high-priced drugs.

Transparency in drug pricing is a key goal of the research, as drug production costs are often shrouded in secrecy. The study sheds light on the costs associated with producing diabetes drugs like Ozempic, revealing that the biggest cost is not the active medicine itself but the disposable pens used for injection.

The debate over drug pricing is intensifying, with state health plans and Medicaid offices grappling with soaring costs for drugs like Ozempic and Wegovy. The study found that while the active drug in Ozempic is expensive to produce, the overall cost is largely driven by the disposable injection pens and other filling and chemical ingredients.

Despite the high costs of production, the study suggests that there is room for price reduction to make these drugs more accessible to patients. With patents for Ozempic and Wegovy set to expire in 2033, there may be opportunities for generic alternatives that could lower prices significantly.

Overall, the study underscores the need for greater transparency in drug pricing and a reevaluation of what constitutes a fair price for essential medications. As the debate over drug affordability continues to escalate, it is clear that more research and advocacy are needed to ensure that patients can access the medications they need at a reasonable cost.

About The Author

Scroll to Top